Inhaled therapies for pulmonary hypertension

Respiratory Care

Volumn 60, Issue 6, 2015, Pages 794-802

  Hill, Nicholas S ^a   Preston, Ioana R ^a   Roberts, Kari E ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Aerosol therapies; Inhaled nitric oxide; Inhaled route; Pulmonary arterial hypertension; Pulmonary hypertension

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; FASUDIL; ILOPROST; IMATINIB; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; TREPROSTINIL; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTIHYPERTENSIVE AGENT; BRONCHODILATING AGENT; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

ARTICLE; COUGHING; DIARRHEA; FAINTNESS; HEADACHE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOTENSION; NAUSEA; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROAT IRRITATION; TRISMUS; WHEEZING; WITHDRAWAL SYNDROME; ADULT; ANALOGS AND DERIVATIVES; HYPERTENSION, PULMONARY; INHALATIONAL DRUG ADMINISTRATION; NEWBORN; OFF LABEL DRUG USE;

ADMINISTRATION, INHALATION; ADULT; ANTIHYPERTENSIVE AGENTS; BRONCHODILATOR AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFANT, NEWBORN; NITRIC OXIDE; OFF-LABEL USE; PROSTAGLANDINS I; VASODILATOR AGENTS;

EID: 84944720807     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.03927     Document Type: Article

References (32)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-D41.
2. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263(5579): 663-665.
3. Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc 1979;38(1):66-71.
4. Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol 2008;214(2):434-441.
5. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334(5):296-301.
6. De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004;127(4):1058-1067.
7. Preston IR, Sagliani KD, Roberts KE, Shah AM, Desouza SA, Howard W, et al. Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ 2013;3(1):68-73.
8. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, Schmehl T. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003;124(4):1294-304.
9. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-329.
10. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld- Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160(2):600-607.
11. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51(2):161-169.
12. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005;28(6):882-888.
13. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48(8):1672-1681.
14. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915-1922.
15. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012;110(10):1546-1550.
16. Preston IR, Feldman J, White J, Franco V, Ishizawar D, Burger C, et al. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. Pulm Circ 2014;4(3):456-461.
17. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006;(176 Pt 1):213-254.
18. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003; 54(4):469-487.
19. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111(23):3105-3111.
20. Malhotra R, Hess D, Lewis GD, Bloch KD, Waxman AB, Semigran MJ. Vasoreactivity to inhaled nitric oxide with oxygen predicts longterm survival in pulmonary arterial hypertension. Pulm Circ 2011; 1(2):250-258.
21. Bhorade S, Christenson J, O’Connor M, Lavoie A, Pohlman A, Hall JB. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999;159(2):571-579.
22. Christenson J, Lavoie A, O’Connor M, Bhorade S, Pohlman A, Hall JB. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000;161(5):1443-1449.
23. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91(1):307-310.
24. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996;109(6):1545-1549.
25. Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001;120(3):866-872.
26. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001;29(5):1000-1005.
27. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970;225(5235):863-864.
28. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111(9):1339-1346.
29. Galie N, Boonstra A, Ewert R, Gomez-Sanchez MA, Barbera JA, Torbicki A, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH) (abstract). Am J Respir Crit Care Med 2010;181:A2516.
30. Loirand G, Guèrin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98(3):322-334.
31. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171(5):494-499.
32. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galiè N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127(10):1128-1138.